Falk Gastro Review Journal

Current science, compiled for you from the multitude of scientific publications – this is the Falk Gastro Review Journal.

Dunkel- bis hellblaue Grafik einer Tonspur-Frequenz auf orangem Hintergund.

The latest issues

Edition 3/2024

Edition 2/2024

Edition 1/2024

Find here all FGR publications since mid-2022 selected and reviewed from international medical journals. Click here above to browse the individual quarterly issues or use the filters below or click chronologically through all articles.

All articles

Curcumin-QingDai combination for patients with active ulcerative colitis: A randomized, double-blinded, placebo-controlled trial

Clin Gastroenterol Hepatol. 2024;22(2):347–56.e6

Outcome of biological therapies and small molecules in ulcerative proctitis: A Belgian multicenter cohort study

Clin Gastroenterol Hepatol. 2024;22(1):154–63.e3

Hormonal contraceptives reduce active symptomatic disease but may increase intestinal inflammation in IBD

J Clin Gastroenterol. 2024;58(3):271–6

Short-term psychodynamic psychotherapy in addition to standard medical therapy increases clinical remission in adolescents and young adults with inflammatory bowel disease: A randomized controlled trial

J Crohns Colitis. 2024;18(2):256–63

Risk of cancer recurrence in patients with immune-mediated diseases with use of immunosuppressive therapies: An updated systematic review and meta-analysis

Clin Gastroenterol Hepatol. 2024;22(3):499–512.e6

Dual biologic or small molecule therapy in refractory pediatric inflammatory bowel disease (DOUBLE-PIBD): A multicenter study from the Pediatric IBD Porto Group of ESPGHAN

Inflamm Bowel Dis. 2024;30(2):159–66

Dysbiosis and associated stool features improve prediction of response to biological therapy in inflammatory bowel disease

Gastroenterology. 2024;166(3):483–95

Thiopurines have sustained long-term effectiveness in patients with inflammatory bowel disease, which is independent of disease duration at initiation: A propensity score matched analysis

J Crohns Colitis. 2024;18(2):192–203

Treatment of non-constipated irritable bowel syndrome with the histamine 1 receptor antagonist ebastine: A randomized, double-blind, placebo-controlled trial

Gut. 2024;73(3):459–69